4 research outputs found
Phosphoâregulation, nucleotide binding and ion access control in potassiumâchloride cotransporters
Potassiumâcoupled chloride transporters (KCCs) play crucial roles in regulating cell volume and intracellular chloride concentration. They are characteristically inhibited under isotonic conditions via phosphoâregulatory sites located within the cytoplasmic termini. Decreased inhibitory phosphorylation in response to hypotonic cell swelling stimulates transport activity, and dysfunction of this regulatory process has been associated with various human diseases. Here, we present cryoâEM structures of human KCC3b and KCC1, revealing structural determinants for phosphoâregulation in both Nâ and Câtermini. We show that phosphoâmimetic KCC3b is arrested in an inwardâfacing state in which intracellular ion access is blocked by extensive contacts with the Nâterminus. In another mutant with increased isotonic transport activity, KCC1Î19, this interdomain interaction is absent, likely due to a unique phosphoâregulatory site in the KCC1 Nâterminus. Furthermore, we map additional phosphorylation sites as well as a previously unknown ATP/ADPâbinding pocket in the large Câterminal domain and show enhanced thermal stabilization of other CCCs by adenine nucleotides. These findings provide fundamentally new insights into the complex regulation of KCCs and may unlock innovative strategies for drug development
Phospho-regulation, nucleotide binding and ion access control in potassium-chloride cotransporters
Potassium-coupled chloride transporters (KCCs) play crucial roles
in regulating cell volume and intracellular chloride concentration.
They are characteristically inhibited under isotonic conditions via
phospho-regulatory sites located within the cytoplasmic termini.
Decreased inhibitory phosphorylation in response to hypotonic cell
swelling stimulates transport activity, and dysfunction of this
regulatory process has been associated with various human
diseases. Here, we present cryo-EM structures of human KCC3b
and KCC1, revealing structural determinants for phosphoregulation in both N- and C-termini. We show that phosphomimetic KCC3b is arrested in an inward-facing state in which
intracellular ion access is blocked by extensive contacts with the
N-terminus. In another mutant with increased isotonic transport
activity, KCC1D19, this interdomain interaction is absent, likely
due to a unique phospho-regulatory site in the KCC1 N-terminus.
Furthermore, we map additional phosphorylation sites as well as a
previously unknown ATP/ADP-binding pocket in the large Cterminal domain and show enhanced thermal stabilization of
other CCCs by adenine nucleotides. These findings provide fundamentally new insights into the complex regulation of KCCs and
may unlock innovative strategies for drug development
Using hybrid approaches to study the allosteric regulation of GTP cyclohydrolase I
Guanosine triphosphate (GTP) cyclohydrolase I (GCH1) catalyzes the conversion of GTP to dihydroneopterin triphosphate (H2NTP), the initiating step in the biosynthesis of tetrahydrobiopterin (BH4). Besides other roles, BH4 functions as cofactor in neurotransmitter biosynthesis. The BH4 biosynthetic pathway and GCH1 have been identified as promising targets to treat pain disorders in patients. The function of mammalian GCH1s is regulated by a metabolic sensing mechanism involving a regulator protein, GCH1 feedback regulatory protein (GFRP). GFRP binds to GCH1 to form inhibited or activated complexes dependent on availability of cofactor ligands, BH4 and phenylalanine, respectively. We determined high-resolution structures of human GCH1âGFRP complexes by cryoelectron microscopy (cryo-EM). Cryo-EM revealed structural flexibility of specific and relevant surface lining loops, which previously was not detected by X-ray crystallography due to crystal packing effects. Further, we studied allosteric regulation of isolated GCH1 by X-ray crystallography. Using the combined structural information, we are able to obtain a comprehensive picture of the mechanism of allosteric regulation. Local rearrangements in the allosteric pocket upon BH4 binding result in drastic changes in the quaternary structure of the enzyme, leading to a more compact, tense form of the inhibited protein, and translocate to the active site, leading to an open, more flexible structure of its surroundings. Inhibition of the enzymatic activity is not a result of hindrance of substrate binding, but rather a consequence of accelerated substrate binding kinetics as shown by saturation transfer difference NMR (STD-NMR) and site-directed mutagenesis. We propose a dissociation rate controlled mechanism of allosteric, noncompetitive inhibition
Phosphoâregulation, nucleotide binding and ion access control in potassiumâchloride cotransporters
Potassiumâcoupled chloride transporters (KCCs) play crucial roles in regulating cell volume and intracellular chloride concentration. They are characteristically inhibited under isotonic conditions via phosphoâregulatory sites located within the cytoplasmic termini. Decreased inhibitory phosphorylation in response to hypotonic cell swelling stimulates transport activity, and dysfunction of this regulatory process has been associated with various human diseases. Here, we present cryoâEM structures of human KCC3b and KCC1, revealing structural determinants for phosphoâregulation in both Nâ and Câtermini. We show that phosphoâmimetic KCC3b is arrested in an inwardâfacing state in which intracellular ion access is blocked by extensive contacts with the Nâterminus. In another mutant with increased isotonic transport activity, KCC1Î19, this interdomain interaction is absent, likely due to a unique phosphoâregulatory site in the KCC1 Nâterminus. Furthermore, we map additional phosphorylation sites as well as a previously unknown ATP/ADPâbinding pocket in the large Câterminal domain and show enhanced thermal stabilization of other CCCs by adenine nucleotides. These findings provide fundamentally new insights into the complex regulation of KCCs and may unlock innovative strategies for drug development